MAMMOGRAPHY
A mammogram is a low-dose x-ray of breast tissue. A screening mammogram is done if a woman has no breast complaints. When a woman presents with a breast problem or has a history of breast cancer, a diagnostic mammogram is done. Screening mammography is the only test to date to have resulted in a decreased mortality rate from breast cancer. It must be performed correctly and on the appropriate female population to be effective. Appropriate client preparation and effective imaging technique are necessary.
Premenopausal women should attempt to schedule the examination during the first 10 days of the menstrual cycle. Changes can occur in the breast tissue later in the cycle that create a potentially confusing appearance. Deodorant should not be worn on the day of the test because it can create white spots that can be mistaken for calcifications. Appropriate imaging technique requires adequate compression; women can use a mild pain reliever such as ibuprofen or acetaminophen to minimize discomfort. A questionnaire addressing personal and family history is completed before the examination.
Imaging can be performed either with traditional screen-film mammography or with digital technique, with images stored on a computer rather than on film. The two are equally effective in a general population. Digital mammography has been shown to be more effective for women who are younger than age 50, who are pre-or perimenopausal, and who have dense breasts (i.e., significantly more tissue than fat) (Pisano, Gatsonis, et al., 2008; .
A screening mammogram consists of two views of each breast. The compression is applied from the top to the bottom of the breast for the craniocaudal view, and from side to side for the mediolateral oblique view. Additional views may be obtained as needed. Women with implants, for instance, receive an additional pair of images. One set is of images of the implants; the other one is done with the implants "pushed back" to optimally compress and image the tissue.
A screening mammogram is performed in 10 to 15 minutes; images are then presented to the radiologist for interpretation. The radiologist reviews the woman's history and compares the images to any prior films. Subtle changes between successive mammograms are often the earliest clue to a developing cancer. These changes can take the form of a suspicious pattern of calcifications, a mass, or an area of disorganized breast tissue. When any of these changes are detected on a screening mammogram, the woman is asked to return for diagnostic imaging.
Diagnostic mammograms are also performed for women who present with a breast problem or concern such as a lump (including an enlarged axillary lymph node), bloody nipple discharge, nipple or skin changes, or pain localized to one area of the breast (focal pain). Other indications include prior breast cancer, biopsies showing changes associated with future increased risk for breast cancer ("high-risk lesions"), and male gender. Diagnostic mammograms often include additional views and
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NEW MAMMOGRAPHY SCREENING GUIDELINES
New guidelines for screening mammography were issued by the U.S. Preventive Services Task On the basis of their reviews of the research, the Task Force recommended screening mammograms every 2 years for women age 50 to 74, advised against routine screening for women age 40 to 49 (individual decision to be made after consultation with a referring health care provider), and issued no recommendation for women older than 75. These guidelines are based on conflicting computer models and appear to confer significance to the age of 50, which is an arbitrary threshold. They are in marked contrast to the current ACS recommendations advocating annual mammography starting at age 40.
The breast cancer mortality rate in the United States has decreased by almost 30% since 1990, coinciding with implementation of large-scale breast screening (Kopans, 2002) . In the prior 50 years, this rate had remained unchanged despite advances in treatment. Breast cancer incidence increases with age. One in 67 women age 40 to 49 will develop an invasive carcinoma. Starting screening at age 50 would sacrifice 33 years of life per 1,000 women screened.
Screening every other year between ages 50 and 74 would miss 19% to 33% of the cancers otherwise detected on annual examination. These cancers would continue to grow before being discovered at a more advanced stage.
Breast cancer incidence continues to increase among women older than 75. A decision to continue screening needs to be weighed against the woman's health history. Life expectancy needs to be 5 years or more for breast screening to show a benefit.
The Task Force also emphasized the "harms" of screening mammography (i.e., recall for additional imaging and biopsies). In breast imaging centers across the United States, the average recall rate is 10% to 15% and only 1% to 2% of women screened will require a biopsy. This needs to be weighed against breast cancer incidence.
The Task Force also raised the issue of "over diagnosis" and "overtreatment" of breast cancer, while admitting that, "Methods for estimating over diagnosis at a population level
Risk Factors for Breast Cancer
"Fixed" risk factors 1. Gender-women are 100 times more likely to be diagnosed than are men.
2. Age-breast cancer incidence increases with age, from 1:233 at ages 30 to 39 to 1:27 at ages 60 to 69.
3. Genetics-carriers of mutations of the breast cancer (BrCA) 1 and 2 genes are at significantly increased risk (60% to 80% lifetime risk) for developing breast cancer. Although relatively uncommon in the general population (1:500 to 1:1,000), these mutations are frequent in Jewish (particularly Ashkenazi) women (1:50).
4. Family history-breast cancer in a first-degree relative (mother, sister) doubles a woman's risk; two affected first-degree relatives increase the risk about fivefold.
5. Prior breast cancer-results in a threefold to fourfold risk of developing a new cancer in the same or opposite breast.
6. Previous biopsy-certain benign findings in a biopsy lead to a future increased risk of developing a breast malignancy. For atypical ductal and lobular hyperplasia, the risk is 4 to 5 times greater than average; for lobular carcinoma in situ, it is 7 to 11 times greater.
7. race and ethnicity-White women are more likely to develop breast cancer than are African American women, but the latter are more likely to die. This could be due to more aggressive tumors or delayed access to diagnosis and treatment. Breast cancer is less prevalent among Native American, Asian, and Hispanic women than among White women.
8. Breast density-women with very dense breast tissue have a nearly fivefold increased risk compared to women with predominantly fatty tissue.
9. Menstrual history-early menarche (before age 12) and late menopause (after age 55) are associated with a slightly higher risk because of prolonged hormonal stimulation.
Lifestyle-related risk factors (i.e., can be changed or manipulated)
1. Hormone replacement therapy-postmenopausal hormone replacement. risk returns to that of the general population 5 years after it is discontinued.
2. Alcohol-more than 1 drink daily increases the risk.
3. Weight-obesity increases the risk after menopause by a factor of 1.5.
4. Physical activity-exercise in any form decreases risk. Boyd et al. (2007), and Mayo Clinic (2007 
Note. Data from American Cancer Society (2009),

ROLE OF ULTRASOUND IN BREAST IMAGING
Ultrasound employs sound waves to create images of the breast. Advantages include lack of radiation, lack of special preparation on the part of the woman, and the ability to provide real-time imaging guidance for procedures such as needle core biopsy and fine needle aspiration. Ultrasound is used primarily as a diagnostic tool and can characterize masses identified on physical examination or mammogram as solid or fluid filled (cysts). Ultrasound can also be used to identify dilated ducts and intraductal masses when a woman presents with spontaneous bloody nipple discharge, and to evaluate for a fluid collection (abscess) in the setting of inflammation or mastitis. However, ultrasound has limited ability to evaluate calcifications (unless associated with a mass), is dependent on the operator, and can cause false positives.
Ultrasound is not currently used as a screening tool, although its use for screening purposes is controversial. Although ultrasound can detect occasional cancers occult at mammography, its use in a large-scale screening population is limited by the unacceptable number of false positives, which in turn lead to biopsies, causing an emotional and financial burden for women (Berg et al., 2008) . Women who are at high risk (as defined by the ACS) for developing breast cancer and cannot undergo supplemental screening magnetic resonance imaging (MRI) may benefit from screening ultrasound in conjunction with mammography.
ROLE OF MRI IN BREAST IMAGING
MRI has become a valuable adjunct to mammography and ultrasound. Images are created using a large magnet, radiofrequency pulses, a dedicated breast coil, and a computer-based algorithm to reconstruct the images. Women must be screened for metallic objects such as aneurysm clips or certain vascular stents prior to examination. MRI does not expose women to ionizing radiation. A contrast agent is injected intravenously when evaluating for a malignancy; the injection is not required when assessing implant integrity.
Breast MRI is used for both diagnostic and screening purposes. In the diagnostic work-up of a breast cancer, MRI assists with evaluating the extent of disease, including chest wall or muscle involvement, and may show additional disease in the same or opposite breast. MRI has greater sensitivity and specificity than mammogram, ultrasound, or physical examination in assessing response to neoadjuvant chemotherapy. Other indications for MRI include evaluating women presenting with metastatic involvement of the axillary lymph nodes whose malignancy is occult on mammogram and in distinguishing surgical scar from recurrence. A non-oncologic indication for MRI is evaluating silicone implants for leakage or rupture.
The ACS outlined indications for using MRI for screening, and recommended that women at high risk undergo annual screening MRI in addition to mammography (Saslow et al., 2007) . Included in the high-risk population are women with (1) breast cancer (BRCA) 1 and 2 gene mutations or a first-degree relative with the gene mutation; (2) a history of radiation to the chest between ages 10 and 30; and (3) a lifetime risk greater than 20%.
The ACS expert panel concluded that insufficient information was available regarding whether to recommend supplemental MRI for women with a history of breast cancer, dense breast tissue, a high-risk lesion on a prior biopsy, or a lifetime risk of 15% to 20%. They recommended against screening MRI for women with a lifetime risk of 15% or less.
Risk is calculated with a variety of tools, the most widely used being the Gail model (Gail et al., 1989) . This model is available on the National Cancer Institute's website (www.cancer.gov).
CONCLUSION
Imaging has played a significant role in the fight against breast cancer. Mortality from the disease has decreased by almost 30% since 1990, paralleling implementation of largescale annual screening mammography. Women at high risk as defined by the ACS should also undergo annual MRI. Ultrasound is primarily used as a diagnostic tool. Where community resources are available, occupational health nurses may want to consider bringing a mobile mammography unit to the worksite to provide a convenient screening service for women.
